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First Report of Sphingomonas koreensis as a Human Pathogen in a
Patient with Meningitis
Lis H. Marbjerg,a,b Shahin Gaini,a Ulrik S. Justesenc
Department of Infectious Diseases, Odense University Hospital, Odense, Denmarka; Department of Clinical Microbiology, Vejle Hospital, Vejle, Denmarkb; Department of
Clinical Microbiology, Odense University Hospital, Odense, Denmarkc
Sphingomonas koreensis is an aerobic Gram-negative rod originally described in 2001 following isolation from natural mineral
water in Korea. Here, we report a case study with Sphingomonas koreensis as the causative agent of meningitis. To our knowl-
edge, this is the first documented case of Sphingomonas koreensis as a human pathogen.
CASE REPORT
In 1997, a 14-year-old female patient underwent surgery due to asyrinx in the cervical portion of her medulla. A cystoperitoneal
shunt system was inserted, and the column was stabilized with
pedicle screws and metal plates corresponding to T1-T2 and
T11-T12.
In 2003, she was diagnosed with secondary amenorrhea due to
a pituitary adenoma. A transsphenoidal resection of the tumor
was attempted in 2005, but bleeding resulted in the operation
being unsuccessful.
In November 2012, the patient was diagnosed with bacterial
meningitis. The cerebrospinal fluid (CSF) showed the following:
elevated leukocytes of 290 nucleated cells/l with 80% neutro-
phils, protein concentration at 0.7 g/liter, and CSF glucose con-
centration of 1.1 mmol/liter. No bacteria were observed in a con-
centrated Gram stain of the CSF, but Staphylococcus epidermidis
and Staphylococcus warneriwere isolated. After susceptibility test-
ing of the two isolates, the patient received a 2-week course of
intravenous ceftriaxone (4 g once daily). Twelve days after stop-
ping the ceftriaxone treatment, the symptoms of meningitis re-
turned. The CSF showed elevated leukocytes of 853 nucleated
cells/l with 85%neutrophils, protein concentration at 0.6 g/liter,
and CSF glucose concentration of 0.6 mmol/liter. Again, no bac-
teria were observed in a concentrated Gram stain, but S. epidermi-
dis was cultured from the CSF and intravenous ceftriaxone was
reinstituted. Initially, the clinical response was satisfactory; how-
ever, the symptoms recurred in January 2013. Following this re-
currence, the decision was made to switch the treatment plan to
intravenous meropenem (2 g three times a day) and intravenous
vancomycin (1 g twice daily). Treatment with intravenous mero-
penem and vancomycin continued until the removal of the shunt
system in February 2013. It should be noted that the peritoneal
part of the shunt system could not be removed. The remaining
part had no interaction with the central nervous system.
Two weeks after surgical removal of the shunt, the patient was
admitted to the Department of Infectious Diseases with a head-
ache, stiff neck, and confusion. The CSF showed the following:
elevated leukocytes of 335 nucleated cells/l with 70% neutro-
phils, protein concentration of 1.2 g/liter, and CSF glucose con-
centration of 0.6 mmol/liter. Treatment with intravenous mero-
penem (2 g three times a day) and vancomycin (1 g twice daily)
was initiated, and temporary external lumbar drainage was per-
formed. Amagnetic resonance imaging scan showed a cranionasal
fistula at the point of the previous transsphenoidal resection from
2005. Subsequently, a brain computed tomography showed two
osseous defects in the sphenoid sinus. Blood cultures taken at the
time of admission were without growth, but Sphingomonas kore-
ensis was cultured from the CSF. The CSF was taken before initi-
ation of antibiotic treatment, and no bacteria were observed in a
concentrated Gram stain. Additional CSF cultures taken from the
lumbar drain over a 3-day period in late February and March did
not result in growth. However, 5 days following hospitalization, S.
koreensis was cultured again from the CSF. Treatment with intra-
thecal gentamicin (8 mg once daily) was added to the intravenous
meropenem and vancomycin treatment, and the lumbar drain
was replaced. Cultivation of the tip of the drain was without
growth. After antimicrobial susceptibility testing, the antibiotic
treatment was changed to oral trimethoprim-sulfamethoxazole
(80/400 mg twice daily). The two osseous defects in the sphenoid
sinus were surgically repaired during the hospitalization period.
Slowly, the lumbar drainage was reduced, which concluded with
removal of the drain and discharge of the patient in late March
2013. On discharge, she had received a total of 3 weeks of treat-
ment with oral trimethoprim-sulfamethoxazole.
In September 2013, the patient was readmitted to the Depart-
ment of InfectiousDiseases presentingwith fatigue, headache, and
neck pain that had been increasing in severity over 3 to 4 days. The
patient described the symptoms as being similar to those of the
previous episode of meningitis. The clinical examination revealed
no neck stiffness, and she was fully conscious. Her temperature
was 37.5°C. The CSF showed 45 nucleated cells/l, of which 27
were neutrophils. The protein concentration was normal at 0.34
g/liter, but the glucose concentration was low at 1.6 mmol/liter
compared to a serum glucose of 6.3mmol/liter. Laboratory results
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showed a C-reactive protein concentration of3.0 mg/liter (nor-
mal range of6 mg/liter), leukocytes of 10.4 109/liter (normal
range of 3.5  109 to 8.8  109/liter), and a neutrophil count of
8.96  109/liter (normal range of 1.5  109 to 7.5  109/liter).
Treatment with intravenous ceftriaxone (4 g once daily) and in-
travenous vancomycin (1 g twice daily) was initiated. No bacteria
were observed in a concentrated Gram stain of the CSF taken at
the time of admission, but again, S. koreensis was cultured. Blood
and urine cultures were without growth.
It was decided to treat the second episode of S. koreensis men-
ingitis with higher doses of oral trimethoprim-sulfamethoxazole
(240/1,200mg four times daily). The patient weighed 50 kg, and it
was suspected that the dosage used for the previous episode had
been inadequate. However, the dosage had to be reduced to 160/
800mg four times daily after 12 days of treatment, due to increas-
ing side effects (fatigue and nausea). After a total of 3 weeks of oral
trimethoprim-sulfamethoxazole treatment, she received another
2 weeks of treatment with oral moxifloxacin (400 mg once daily).
To date, which is more than a year, the patient has had no recur-
rent symptoms of meningitis.
The two isolates of S. koreensis from February and September
2013 were isolated at the same department of clinical microbiol-
ogy. For both episodes, growth (yellow colonies) was observed
from the two spinal fluid samples on 5% horse blood agar after 72
h of incubation (Fig. 1). Colonies were examined with matrix-
assisted laser desorption ionization–time of flight mass spectrom-
etry (MALDI-TOF MS), using the Shimadzu/SARAMIS system
(Shimadzu Corporation, Kyoto, Japan, and Anagnos-Tec GmbH,
Potsdam-Golm, Germany). The system comprises an Axima As-
surance mass spectrometer system (Shimadzu Corporation) and
the Shimadzu Biotech Launchpad software program and the
SARAMIS database application. The system was operated with a
matrix consisting of-cyano-4-hydroxycinnamic acid in acetoni-
trile, ethanol, and water from Anagnos-Tec GmbH. Both isolates
obtained an unambiguous diagnosis of Sphingomonas koreensis
with a score of 99.9.
The second isolate was also subjected to partial 16S rRNA gene
sequencing (MicroSeq 500 system; Perkin-Elmer, Applied Biosys-
tems Division, Foster City, CA) to confirm the MALDI-TOF di-
agnosis. The isolate consensus sequence (433 bp) had a 100%
match to the Sphingomonas koreensis type strain JSS-26 (T)
(GenBank accession no. AF131296). There was good separation
from the second best match, Sphingomonas soli type strain T5-04
(T) (98.61%) (GenBank accession no. AB166883), and from Sph-
ingomonas paucimobilis type strain ATCC 29837 (T) (94.23%)
(GenBank accession no. U37337). Primary antimicrobial suscep-
tibility testing was performed using the standard EUCAST disk
diffusion method on Mueller-Hinton agar, although no zone di-
ameter breakpoints are available. For the following antimicrobial
agents, no zones were present: ampicillin, piperacillin-tazobac-
tam, ceftriaxone, aztreonam, meropenem, and gentamicin.
However, zones were present for ciprofloxacin,moxifloxacin, and
trimethoprim-sulfamethoxazole. Antimicrobial susceptibility
testing for these three antibiotics was performed with a gradient
MIC method (Etest; bioMérieux, Lyon, France) on Mueller-Hin-
ton agar. The following MICs were obtained: 0.75 mg/liter for
ciprofloxacin, 0.19 mg/liter for moxifloxacin, and 0.047 mg/liter
for trimethoprim-sulfamethoxazole.
The genus Sphingomonaswas first proposed in 1990. It is char-
acterized by the fact that the cellular lipids contain sphingoglyco-
lipids, and the major respiratory quinone is ubiquinone 10 (1). It
is a Gram-negative, strictly aerobic and nonfermentative rod (1).
The genus has since been divided into 4 genera: Sphingomonas
sensu stricto, Sphingobium, Novosphingobium, and Sphingopyxis
(2). S. koreensis was originally described in 2001, after it was dis-
covered inmineral water inKorea, hence the name “koreensis” (3).
It is motile with a single polar flagellum and catalase, oxidase, and
beta-galactosidase positive. Colonies are opaque and yellow (3). It
is possible that S. koreensis could have been misidentified as an-
other Sphingomonas species based on phenotypic characteristics.
However, the biochemical profile differs significantly from other
Sphingomonas species, and, with, e.g., the API ID system, it should
be possible to separate the different species (3).
Little is known about the S. koreensis susceptibility pattern. In
one study, the antimicrobial susceptibilities of 27 different strains
of Sphingomonas sensu stricto were tested using the ATB PSE5
strips (bioMérieux) (4). The isolates were tested at one or two
concentrations. At a colistin concentration of 2mg/liter, 92.6% of
the strains showed growth, 29.6% at a meropenem concentration
of 8mg/liter, 25.9% at a ciprofloxacin concentration of 2mg/liter,
3.7% at a gentamicin concentration of 8 mg/liter, and 55.6% at a
piperacillin-tazobactam concentration of 16 mg/liter (4). The
strain isolated from our patient had low ciprofloxacin, moxifloxa-
cin, and trimethoprim-sulfamethoxazole MICs, which was the
reason why trimethoprim-sulfamethoxazole and subsequently
moxifloxacin were chosen for treatment.
To our knowledge, this is the first report of S. koreensis as a
human pathogen. Anothermember of the Sphingomonas genus, S.
paucimobilis, is an opportunistic pathogen associated with both
nosocomial and community-acquired infections (5–8). S. pauci-
mobilis is considered to be a low-virulence organism, and mortal-
FIG 1 Sphingomonas koreensis on 5% horse blood agar.
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ity rates associated with S. paucimobilis have been reported to be
close to zero in three reviews, though it has been associated with
septic shock (5–7). A mortality rate of 5.5% (3 of 55 patients) has
been reported; however, mortality was believed to be associated
with patient comorbidity in the study (8). S. paucimobilis has been
associated with a wide range of infections, such as pneumonia,
intravascular catheter-related infections, skin and soft tissue in-
fections, urinary tract infections, and meningitis (5–8). Another
Sphingomonas sp., Sphingomonasmucosissima, has been described
to cause bacteremia (9).
In our case, it is likely that S. koreensiswas present in the central
nervous system in the time period between first isolation (Febru-
ary 2013) and final occurrence and hospitalization (September
2013). S. koreensis has been isolated only on the two occasions
described in this report at our Department of Clinical Microbiol-
ogy. Accordingly, it seems very unlikely that the patient was rein-
fected after the first attempt of antibiotic treatment. It is more
likely that treatment failure caused by insufficient doses of trim-
ethoprim-sulfamethoxazole was responsible for the reoccurrence.
There are two possible explanations for the introduction of S.
koreensis into the central nervous system. It could have been in-
troduced during the removal surgery of the cystoperitoneal shunt
system in February 2013 or through the two osseous defects in the
sphenoid sinus. S. koreensis must be considered to be a low-viru-
lence organism, and this could explainwhy the patientwas asymp-
tomatic for several months between February and September
2013. Furthermore, when she presented at our department in Sep-
tember 2013, it waswith relativelymild symptoms, and she had no
fever. The diagnosis of meningitis was made because the patient
was known to have recurrent meningitis and because the patient
described the symptoms as being similar to those of the previous
episode. The exact origin of the S. koreensis is unknown. As a
commensal of the environment, including natural mineral water,
there could be multiple sources.
This case demonstrates the importance of species identifica-
tion, even if isolates are considered or suspected to be contami-
nants. In this case, the finding of S. koreensis at the second episode
of meningitis clearly indicates that this was a true pathogen and
the cause of meningitis in the patient. In conclusion, the unique
case we report here indicates that antibiotic therapy should be
directed against the specific organism, S. koreensis.
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